Blog
RSS FeedPosted by Michael Wonder on 27 Mar 2023
Final reconciliation of savings from side agreements for the full year 2022
28 March 2023 - The TLV has presented the Government with the final reconciliation of the outcome of savings from ...
Posted by Michael Wonder on 16 Feb 2023
Health economic assessment of Kimmtrak in disseminated ocular melanoma
16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the ...
Posted by Michael Wonder on 06 Feb 2023
TLV proposes a new process for health economic assessments that are made in a short time and under special circumstances
1 February 2023 - In a report to the government, the Dental and Pharmaceutical Benefits Agency, TLV, presents experiences and lessons ...
Posted by Michael Wonder on 22 Aug 2022
New handbook on health economic assessments of medical devices
18 August 2022 - TLV carries out health economic assessments of medical technology products at the request of the Medical Technology ...
Posted by Michael Wonder on 04 Jul 2022
TLV reconsiders Orkambi's subsidy
4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives assignments for medicines for rare diseases
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to analyse and make ...
Posted by Michael Wonder on 27 Jun 2022
TLV receives a new assignment on precision medicine and ATMP
27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to continue the work ...
Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...